UNSPSC 51293802: Modaline

This classification denotes an antidepressant agent with the molecular formula C10H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M6T2W2993, chemically known as 2-methyl-3-piperidin-1-ylpyrazine but generally known as modaline, which bears US NIH Compound Identifier 17859. The term modaline is an International Non-Proprietary Name or INN. European Medicines Agency schedules modaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09027MIG.

Most nations schedule modaline under HS 29333999 and SITC 51574. As of Q4 2014, MODALINE remains the US FDA Preferred Term for this commodity. SMILES: CC1=NC=CN=C1N2CCCCC2.

UNSPSC 51293802 Modaline, a Commodity code, covers pharmaceutical products and related health-supply systems that state and local governments procure for public health, emergency response, and community health programs. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for opioid-crisis response, generic multi-source pharmaceuticals and over-the-counter products for distributed government health facilities, and exploring direct-to-manufacturer prescription fulfillment models to improve efficiency and reduce costs. The issuing bodies span county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances, with Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration appearing in recent activity.

Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission released an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities and market intelligence on direct-to-manufacturer prescription programs for self-insured employee health plans and state agencies. Recent activity spans Florida, Texas, Minnesota, and Oregon, with cooperative purchasing vehicles playing a significant role alongside individual county and state procurements.